Prucalopride accepted by NICE

Prucalopride (Resolor) has been recommended by NICE as a possible treatment for women with chronic constipation.

According to the new guidance, women are eligible to receive the 5HT4 agonist on the NHS if:

  • they have tried at least two different types of laxatives at the highest tolerated recommended doses for at least 6 months, without adequate relief
  • invasive treatment of constipation is being considered.

Prucalopride should be prescribed only by a clinician experienced in treating chronic constipation, who has carefully reviewed the woman’s previous laxative use. Treatment should be reviewed after 4 weeks.

Prucalopride was launched in January 2010. Marketing authorisation was granted for use only in women as regulators felt that the drug had not been sufficiently evaluated in men.

View Resolor drug record

Further information: Movetis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases